# Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II

> **NCT07686926** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 36 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Becotatug Vedotin
- **DRUG:** Tislelizumab
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT07686926
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2028-07-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07686926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07686926, "Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07686926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*